From July 2001 to April 2004, we used leflunomide as the initial antiviral therapy in 17 patients with biopsy-proven BK nephropathy. All but one of these patients was receiving tacrolimus, prednisone, ...

Active surveillance for BK virus with prompt reduction in immunosuppression therapy may help minimize graft loss due to BK nephropathy. Renal infection with BK virus is associated with poor allograft ...

BOSTON—Retransplantation after kidney graft loss due to BK virus nephropathy appears to be safe and feasible. However, replacing alemtuzumab with basiliximab may be necessary to achieve optimal ...

For kidney transplant recipients with a serious complication called BK virus-associated nephropathy, promptly cutting back on anti-rejection drugs reduces the risk of losing the kidney, according to a ...

Polyomavirus-associated nephropathy (PVAN) remains an important infectious complication after renal transplantation, affecting 1–10% of recipients and causing graft loss in approximately 50% of cases.

Nephropathy associated with the polyomavirus type BK (BKV) nephropathy has emerged as a cause of allograft failure linked to immunosuppressive regimens containing tacrolimus or mycophenolate mofetil.

We retrospectively reviewed clinical information and surgical pathology findings in 113 biopsies from 52 patients with a history of BK virus activation defined as at least one post-transplant episode ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

New Breakthrough Device test expands Roche molecular test menu for transplant patients, enabling simultaneous testing of BK virus with Cytomegalovirus and Epstein-Barr virus Basel, 8 September 2020 - ...

Introduction: The risk of polyomavirus-associated nephropathy (PyVAN) currently ranges from 1% to 10%, and the risk of graft loss is 10% to 50% within 2 years post-diagnosis. There is currently no ...

Introduction: Early prognostic markers that identify high-risk kidney transplant recipients may lead to optimization of immunosuppressive therapy and improved long-term outcomes. Objectives: The aim ...